X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SKY-0515 is a small molecule RNA splicing modifier, designed to reduce the production of the mutated huntingtin protein which results in disease progression. It is being evaluated for the treatment of huntington's disease.
Lead Product(s): SKY-0515
Therapeutic Area: Genetic Disease Product Name: SKY-0515
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2024
Details:
Under the terms of agreement, Sanofi will leverage Skyhawk's proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to address challenging oncology and immunology targets.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $2,054 million Upfront Cash: $54.0 million
Deal Type: Collaboration July 05, 2022
Details:
The collaboration leverages SkySTAR™ platform to discover and develop novel small molecule therapeutics that modulate RNA splicing which have the potential to transform the lives of patients with serious diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $2,240.0 million Upfront Cash: $40.0 million
Deal Type: Collaboration December 22, 2020
Details:
Under the expanded collaboration, Skyhawk will deploy its SkySTARTM platform to develop drug candidates directed to multiple new targets for autoimmune and metabolic diseases. The collaboration now spans neurodegeneration, oncology, autoimmunity, and metabolic diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $600.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
